Delving into the Latest Updates on Unoprostone Isopropyl with Synapse

This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.

Start Date01 Mar 2013

Sponsor / Collaborator

R-Tech Ueno, Ltd.

100 Clinical Results associated with Unoprostone Isopropyl

Login to view more data

100 Translational Medicine associated with Unoprostone Isopropyl

Login to view more data

100 Patents (Medical) associated with Unoprostone Isopropyl

Login to view more data

427

Literatures (Medical) associated with Unoprostone Isopropyl

01 Jun 2022·Reproduction in Domestic AnimalsQ3 · AGRICULTURAL & FORESTRY SCIENCE

Use of serum progesterone and prostaglandin F_2α metabolite levels to predict onset of parturition in the bitch

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Joonè, Carolynne Jane ; Nöthling, Johan Oliviette ; De Cramer, Kurt G. M.

AbstractThe prediction of time to onset of parturition in a preparturient bitch is of great clinical value, particularly for bitches at high risk of dystocia and those lacking relevant clinical data from the time of breeding. In a previous study, four cut‐offs for plasma progesterone levels, measured by radioimmunoassay, were shown to be useful for predicting the likelihood of a bitch entering stage one of parturition within defined time intervals. The first aim of the current study was to evaluate these cut‐offs in a clinical setting, using serum progesterone samples drawn from preparturient bitches 12‐hourly instead of 6‐hourly and assessed using chemiluminescence immunoassay. Furthermore, the use of 13,14‐dihydro‐15‐keto‐prostaglandin F2α, (PGFM), a metabolite of prostaglandin F2α, in predicting the time to onset of parturition was evaluated. Forty bitches carrying two or more foetuses were admitted to a specialist veterinary reproduction hospital 53 d after the onset of cytological dioestrus when that date was known, or 57 d after the last mating. Vaginal speculum examinations were performed every 6 hr until cervical dilatation was visualized (time of cervical dilatation; TCD). Serum samples were collected at 08h00 and 18h00 daily until TCD. All bitches underwent elective caesarean section at TCD. Results of this study show that approximately 5% and 10% of preparturient bitches will reach TCD within 12 hr despite a serum progesterone level of at least 15.8 nmol/L and 8.7 nmol/L respectively. In addition, there is a 95% probability that a preparturient bitch will reach TCD within 48 hr if her serum progesterone level is below 8.7 nmol/L, and a 91% probability of her reaching TCD within 24 hr if her serum progesterone level is below 3.18 nmol/L. Approximately 90% of bitches that demonstrate a 20% increase in PGFM over a 12‐hr period are likely to be within 36 hr of TCD. These results provide useful benchmarks for the management of canine parturition.

01 May 2022·Australasian Journal of DermatologyQ4 · MEDICINE

Topical ophthalmic beta‐blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system

Q4 · MEDICINE

Article

Author: Jedlowski, Mahdieh Fazel ; Jedlowski, Patrick Michael

ABSTRACTBackground/objectiveThe association between antiglaucoma medications and the development of ocular pseudopemphigoid (OPP) has been described; however, the independent risk of each medication has not been quantified.MethodsCase/non‐case analyses were performed in the FDA Adverse Events Reporting System (FAERS) using data from 2010–2020 to examine the reporting odds ratio (ROR) signal for OPP for all classes of antiglaucoma medications under multiple conditions: (i) comparison to all other drugs in FAERs, (ii) comparison to other antiglaucoma medications, (iii) comparison to vehicle/hydrating eye drops with cases of OPP and (iv) comparison to vehicle/hydrating eyedrops with and without cases of OPP to control for topical irritant and preservative effects.ResultsA statistically significant ROR for OPP was found for aggregate antiglaucoma medications under the first condition but not the third or fourth (i.96.97 (95% CI 52.54–178.98). The largest signal for OPP when compared to other glaucoma drugs and eye drops was seen with unoprostone (ii.68.96 (95% CI 8.35–569.50, iii.39.85 (95% CI 4.14–383.33), iv.581.67 (95% CI 49.38–6851.57) followed by carteolol (ii.32.51(95% CI 9.02–117.67), iii.10.67 (95% CI 1.77–64.13), iv.77.84 (95% CI 12.95–467.78) and betaxolol (ii.23.38 (95% CI 7.28–74.46), iii.6.94 (95% CI 1.27–38.01), iv.50.67 (95% CI 9.26–277.25). A statistically significant ROR was noted only for the beta‐blockers class aggregate under conditions ii and iv.ConclusionsOur findings support an association between OPP and antiglaucoma medications; under the most stringent control for topical irritant/preservative effect by of comparison to topical eye drops, unoprostone, carteolol, betaxolol and timolol all had a significant ROR for OPP.

01 May 2022·British Journal of OphthalmologyQ2 · MEDICINE

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

Q2 · MEDICINE

Review

Author: Cui, Amy Xianying ; Barbeau, Martin ; Beauchemin, Catherine ; Royer, Catherine ; Harasymowycz, Paul ; Mathurin, Karine ; Lachaine, Jean ; Jobin-Gervais, Katherine

Background/aimsTo assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).MethodsA systematic literature review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%, latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated.ResultsA total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (−3.45 (−4.77 to −2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed latanoprost (−0.70 (−1.83 to 0.43)) and tafluoprost (−0.41 (−1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(−1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (−0.17 (−1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%.ConclusionLBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%.

100 Deals associated with Unoprostone Isopropyl

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01452	Unoprostone Isopropyl	S01EE02	DB06826

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Nitto Pharmaceutical Industries Ltd.	22 Mar 2007
Ocular Hypertension	JP	Nitto Pharmaceutical Industries Ltd.	22 Mar 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
dry age-related macular degeneration	Discovery	AT	Sucampo Pharmaceuticals LLC	01 May 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2014	Not Applicable	Ocular Hypertension \| Glaucoma, Open-Angle	10	Unoprostone isopropyl 0.15% ophthalmic solution	(ayanzmsbhk) = xxpopnezzk bzyefaoqct (yvsapjfpzx, 1.0)	-	01 Apr 2014
JPRN-UMIN000005514 (ARVO2012)	Not Applicable	Retinitis Pigmentosa	22	High dose UF-021	yyclhtouil(eygegexfad) = yuopcynews tutwihkees (beqlkctbyi ) View more	-	01 Mar 2012
				Low dose UF-021	yyclhtouil(eygegexfad) = bjzxjsydny tutwihkees (beqlkctbyi ) View more
ARVO2009	Not Applicable	Retinitis Pigmentosa	-	Isopropyl Unoprostone (Group A (Improved retinal sensitivity))	(bqdcnwydus) = jdkkxwpcvi usxddtpjgw (hmgvbobewx ) View more	-	01 Apr 2009
				Isopropyl Unoprostone (Group B (No improvement in retinal sensitivity))	(bqdcnwydus) = ozutfgofse usxddtpjgw (hmgvbobewx )
ARVO2008	Not Applicable	matrix metalloproteinases (MMPs) \| tissue inhibitors of metalloproteinases (TIMPs)	13	Latanoprost	(rjwumcbvzb) = jmdavyuagz uqydlvyhge (csyihnxkbg, 7) View more	Positive	01 May 2008
				Bimatoprost	rswvrossdn(kcuqbhency) = mmmilfuvcs hpzlndqyte (vcfzrbfpin, 34) View more
ARVO2007	Not Applicable	-	-	Latanoprost 30 ng/mL	(jqrouscbpu) = jumzigvpws fbviwnecxp (pmtmcayxyu ) View more	-	01 May 2007
				Unoprostone 145 ng/mL	kksjsoulbt(wacwkxhwfl) = bfwyxyjexq khxamtoywa (zocglezmdz ) View more
ARVO2004	Not Applicable	-	-	Travoprost acid	bsqraydaev(ddogxfavlw) = yvpxzmelul tnilifnrab (kyouggbtik ) View more	-	01 May 2004
				Bimatoprost acid	bsqraydaev(ddogxfavlw) = wumzcijvjo tnilifnrab (kyouggbtik ) View more
ARVO2003	Not Applicable	Diabetes Mellitus HbA1c \| ET-1 plasma level	19	Unoprostone isopropyl ophthalmic solution	wtsvudharx(rimssgodmo) = wpqrggfuty yftgbwnxlp (kdplxplqbv ) View more	Positive	01 May 2003
ARVO2003	Not Applicable	Ocular Hypertension	-	Unoprostone 0.15%	(bcdcryanxk) = qqoermbylv uqsmknxfte (jhitshnyog ) View more	Positive	01 May 2003
				Vehicle	(bcdcryanxk) = wuhfzgiibe uqsmknxfte (jhitshnyog ) View more
ARVO2002	Not Applicable	Glaucoma, Open-Angle	25	Latanoprost 0.005%	cghnngghfz(ujdkvsgckf) = rkpjnfuroy rowztppoll (vfmpfquwvp )	Positive	01 Dec 2002
				Unoprostone 0.15%	cghnngghfz(ujdkvsgckf) = ovxjuqyses rowztppoll (vfmpfquwvp )
ARVO2002	Not Applicable	Ocular Hypertension	161	Latanoprost 0.005%	(ttqgjyaefe) = fspdneklhy mfdtmvzadl (vwjlvwgaid, + 3.9)	Positive	01 Dec 2002
				Unoprostone 0.15%	(ttqgjyaefe) = rligouwhym mfdtmvzadl (vwjlvwgaid, + 2.6)